Literature DB >> 18225919

Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.

Nicholas A Malmquist1, Ramesh Gujjar, Pradipsinh K Rathod, Margaret A Phillips.   

Abstract

Plasmodium falciparum dihydroorotate dehydrogenase (pfDHODH) is a flavin-dependent mitochondrial enzyme that provides the only route to pyrimidine biosynthesis in the parasite. Clinically significant inhibitors of human DHODH (e.g., A77 1726) bind to a pocket on the opposite face of the flavin cofactor from dihydroorotate (DHO). This pocket demonstrates considerable sequence variability, which has allowed species-specific inhibitors of the malarial enzyme to be identified. Ubiquinone (CoQ), the physiological oxidant in the reaction, has been postulated to bind this site despite a lack of structural evidence. To more clearly define the residues involved in CoQ binding and catalysis, we undertook site-directed mutagenesis of seven residues in the structurally defined A77 1726 binding site, which we term the species-selective inhibitor site. Mutation of several of these residues (H185, F188, and F227) to Ala substantially decreased the affinity of pfDHODH-specific inhibitors (40-240-fold). In contrast, only a modest increase in the Kmapp for CoQ was observed, although mutation of Y528 in particular caused a substantial reduction in kcat (40-100-fold decrease). Pre-steady-state kinetic analysis by single wavelength stopped-flow spectroscopy showed that the mutations had no effect on the rate of the DHO-dependent reductive half-reaction, but most reduced the rate of the CoQ-dependent flavin oxidation step (3-20-fold decrease), while not significantly altering the Kdox for CoQ. As with the mutants, inhibitors that bind this site block the CoQ-dependent oxidative half-reaction without affecting the DHO-dependent step. These results identify residues involved in inhibitor binding and electron transfer to CoQ. Importantly, the data provide compelling evidence that the binding sites for CoQ and species-selective site inhibitors do not overlap, and they suggest instead that inhibitors act either by blocking the electron path between flavin and CoQ or by stabilizing a conformation that excludes CoQ binding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18225919      PMCID: PMC2868338          DOI: 10.1021/bi702218c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  33 in total

1.  Evolutionary implications of the mosaic pyrimidine-biosynthetic pathway in eukaryotes.

Authors:  T Nara; T Hshimoto; T Aoki
Journal:  Gene       Date:  2000-10-31       Impact factor: 3.688

2.  E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases.

Authors:  Sofie Nørager; Kaj Frank Jensen; Olof Björnberg; Sine Larsen
Journal:  Structure       Date:  2002-09       Impact factor: 5.006

3.  Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.

Authors:  J E McLean; E A Neidhardt; T H Grossman; L Hedstrom
Journal:  Biochemistry       Date:  2001-02-20       Impact factor: 3.162

4.  Dihydrooxonate is a substrate of dihydroorotate dehydrogenase (DHOD) providing evidence for involvement of cysteine and serine residues in base catalysis.

Authors:  O Björnberg; D B Jordan; B A Palfey; K F Jensen
Journal:  Arch Biochem Biophys       Date:  2001-07-15       Impact factor: 4.013

5.  A second dihydroorotate dehydrogenase (Type A) of the human pathogen Enterococcus faecalis: expression, purification, and steady-state kinetic mechanism.

Authors:  J Marcinkeviciene; W Jiang; G Locke; L M Kopcho; M J Rogers; R A Copeland
Journal:  Arch Biochem Biophys       Date:  2000-05-01       Impact factor: 4.013

Review 6.  Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.

Authors:  M L Herrmann; R Schleyerbach; B J Kirschbaum
Journal:  Immunopharmacology       Date:  2000-05

7.  Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism.

Authors:  W Knecht; M Löffler
Journal:  FEBS Lett       Date:  2000-02-04       Impact factor: 4.124

8.  Detergent-dependent kinetics of truncated Plasmodium falciparum dihydroorotate dehydrogenase.

Authors:  Nicholas A Malmquist; Jeffrey Baldwin; Margaret A Phillips
Journal:  J Biol Chem       Date:  2007-02-28       Impact factor: 5.157

9.  Insight into the chemistry of flavin reduction and oxidation in Escherichia coli dihydroorotate dehydrogenase obtained by rapid reaction studies.

Authors:  B A Palfey; O Björnberg; K F Jensen
Journal:  Biochemistry       Date:  2001-04-10       Impact factor: 3.162

10.  Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.

Authors:  Jeffrey Baldwin; Azizeh M Farajallah; Nicholas A Malmquist; Pradipsinh K Rathod; Margaret A Phillips
Journal:  J Biol Chem       Date:  2002-08-19       Impact factor: 5.157

View more
  25 in total

Review 1.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Authors:  Margaret A Phillips; Pradipsinh K Rathod
Journal:  Infect Disord Drug Targets       Date:  2010-06

2.  Contribution of flavin covalent linkage with histidine 99 to the reaction catalyzed by choline oxidase.

Authors:  Osbourne Quaye; Sharonda Cowins; Giovanni Gadda
Journal:  J Biol Chem       Date:  2009-04-27       Impact factor: 5.157

3.  Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.

Authors:  Elumalai Pavadai; Farah El Mazouni; Sergio Wittlin; Carmen de Kock; Margaret A Phillips; Kelly Chibale
Journal:  J Chem Inf Model       Date:  2016-03-08       Impact factor: 4.956

4.  The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.

Authors:  Xiaoyi Deng; David Matthews; Pradipsinh K Rathod; Margaret A Phillips
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-04-21       Impact factor: 1.056

5.  Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance.

Authors:  Amanda K Lukens; Leila Saxby Ross; Richard Heidebrecht; Francisco Javier Gamo; Maria J Lafuente-Monasterio; Michael L Booker; Daniel L Hartl; Roger C Wiegand; Dyann F Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-31       Impact factor: 11.205

6.  Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor.

Authors:  Jennifer L Guler; John White; Margaret A Phillips; Pradipsinh K Rathod
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

7.  Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.

Authors:  Sreekanth Kokkonda; Xiaoyi Deng; Karen L White; Farah El Mazouni; John White; David M Shackleford; Kasiram Katneni; Francis C K Chiu; Helena Barker; Jenna McLaren; Elly Crighton; Gong Chen; Inigo Angulo-Barturen; Maria Belen Jimenez-Diaz; Santiago Ferrer; Leticia Huertas-Valentin; Maria Santos Martinez-Martinez; Maria Jose Lafuente-Monasterio; Rajesh Chittimalla; Shatrughan P Shahi; Sergio Wittlin; David Waterson; Jeremy N Burrows; Dave Matthews; Diana Tomchick; Pradipsinh K Rathod; Michael J Palmer; Susan A Charman; Margaret A Phillips
Journal:  J Med Chem       Date:  2020-04-16       Impact factor: 7.446

8.  Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.

Authors:  Ramesh Gujjar; Alka Marwaha; Farah El Mazouni; John White; Karen L White; Sharon Creason; David M Shackleford; Jeffrey Baldwin; William N Charman; Frederick S Buckner; Susan Charman; Pradipsinh K Rathod; Margaret A Phillips
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

9.  Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.

Authors:  Carolyn K Dong; Vishal Patel; Jimmy C Yang; Jeffrey D Dvorin; Manoj T Duraisingh; Jon Clardy; Dyann F Wirth
Journal:  Bioorg Med Chem Lett       Date:  2008-11-24       Impact factor: 2.823

10.  Roles in binding and chemistry for conserved active site residues in the class 2 dihydroorotate dehydrogenase from Escherichia coli.

Authors:  Rebecca L Fagan; Bruce A Palfey
Journal:  Biochemistry       Date:  2009-08-04       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.